Firm | Analyst |
Raymond James | Michael Freeman |
Stifel GMP | Justin Keywood |
Paradigm Capital | Scott McAuley, PhD |
Maxim Group | Michael Okunewitch |
Research Capital | Andre Uddin |
NervGen Pharma Corp. is followed by the analysts listed above. Please note that any opinions, estimates or forecasts regarding NervGen Pharma Corp.’s performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of NervGen Pharma Corp. or its management. NervGen Pharma Corp. does not by its reference above or distribution imply its endorsement of or concurrence with such information, conclusions or recommendations.
NervGen (TSX-V: NGEN, OTCQB: NGENF) is a clinical-stage biotech company dedicated to developing innovative treatments to enable nervous system repair in the settings of traumatic injury and disease. NervGen’s lead drug candidate, NVG-291, is being evaluated in a Phase 1b/2a clinical trial in the company’s initial target indication, spinal cord injury. NervGen is evaluating a new discovery lead, NVG-300, in a preclinical model of ischemic stroke and confirmatory SCI study.
Contact
112-970 Burrard Street
Unit 1290
Vancouver, BC V6Z 2R4
Phone: (778) 731-1711
Email: info@nervgen.com